 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
18 July 2000 | Volume 133 Issue 2 | Pages 111-122
Background: Growth hormone–deficient adults have increased cardiovascular mortality. Growth hormone replacement may affect cardiovascular risk. Inflammation plays an important role in atherosclerosis, and inflammatory markers are predictive of cardiovascular events.
Objective: To investigate the effect of growth hormone replacement on inflammatory and other cardiovascular risk factors.
Design: Randomized, single-blind, placebo-controlled trial.
Patients: 40 men with adult-onset growth hormone deficiency.
Intervention: Growth hormone or placebo given for 18 months at a dose adjusted for normal serum insulin-like growth factor I level.
Measurements: Anthropometric, hemoglobin A1c, and central fat values were assessed every 6 months. Levels of glucose, insulin, insulin-like growth factor I, and lipids were measured at 1, 3, 6, 12, and 18 months. C-reactive protein, serum amyloid polypeptide A, interleukin-6, and lipoprotein(a) levels were determined at baseline and 6 and 18 months.
Results: C-reactive protein and interleukin-6 levels decreased in growth hormone recipients compared with placebo recipients (differences between groups, –1.9 ± 0.6 mg/L [P = 0.0027] and –1.3 ± 0.5 ng/L [P = 0.013], respectively). Changes in serum amyloid polypeptide A levels between groups did not reach statistical significance (difference between groups, –2.4 ± 1.2 mg/L; P = 0.056). Serum cholesterol levels, low-density lipoprotein cholesterol levels, and ratios of total cholesterol to high-density lipoprotein cholesterol decreased in growth hormone recipients in the first 3 months compared with placebo recipients (differences between groups, –0.86 ± 0.17 mmol/L [–33.2 ± 6.6 mg/dL] [P < 0.001], –0.63 ± 0.20 mmol/L [–24.5 ± 5.9 mg/dL] [P < 0.001], and –0.56 ± 0.26 [P = 0.040], respectively), but the decrease was not maintained from month 6 to month 18. Lipoprotein(a) levels increased (difference between groups, 22.0 ± 8.0 mg/L; P = 0.0096). Short-term increases occurred in glucose levels, insulin levels, and insulin-to-glucose ratios (differences between groups, 0.54 ± 0.16 mmol/L [9.6 ± 2.8 mg/dL] [P = 0.0018], 37.9 ± 9.6 pmol/L [P < 0.001], and 6.0 ± 1.8 [P = 0.0025], respectively), but only the increase in glucose level was maintained over the long term (difference between groups, 0.56 ± 0.17 mmol/L [10.0 ± 3.1 mg/dL]; P = 0.0026). Hemoglobin A1c values did not change. Truncal fat–to–total fat ratios decreased (difference between groups, –0.018 ± 0.007; P = 0.0087).
Conclusions: Long-term growth hormone replacement in men reduces levels of inflammatory cardiovascular risk markers, decreases central fat, and increases lipoprotein(a) and glucose levels without affecting lipid levels.
Author and Article Information
From Massachusetts General Hospital, Harvard Medical School, Brigham and Women's Hospital, and Children's Hospital, Boston, Massachusetts.
Acknowledgments: The authors thank Howard Baum, MD, and the staff of the General Clinical Research Center for patient recruitment and care. They also thank David Schoenfeld, PhD, for statistical advice.
Grant Support: In part by National Institutes of Health grants RR 1066 and DK08783 and Genentech, Inc. Drs. Sesmilo and Llevadot are supported by Fundació "la Caixa," Barcelona, Spain.
Requests for Single Reprints: Anne Klibanski, MD, Neuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 457B, Boston, MA 02114.
Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.
Current Author Addresses: Drs. Sesmilo, Biller, and Klibanski: Neuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 457 B, Boston, MA 02114.
Dr. Llevadot: TIMI Office, Brigham and Women's Hospital, 333 Longwood Avenue, Suite 402, Boston, MA 02115.
Dr. Rifai and Ms. Hanson: Department of Laboratory Medicine and Pathology, Children's Hospital, 300 Longwood Avenue, Farley 7, Boston, MA 02115.
Mr. Hayden: Biostatistics Center, Massachusetts General Hospital, 50 Staniford Street, 5th Floor, Boston, MA 02114.
Author Contributions: Conception and design: G. Sesmilo, B.M.K. Biller, J. Llevadot, N. Rifai, A. Klibanski.
Analysis and interpretation of the data: G. Sesmilo, J. Llevadot, N. Rifai, G. Hanson, D. Hayden, A. Klibanski.
Drafting of the article: G. Sesmilo, A. Klibanski.
Critical revision of the article for important intellectual content: G. Sesmilo, B.M.K. Biller, J. Llevadot, N. Rifai, D. Hayden, A. Klibanski.
Final approval of the article: G. Sesmilo, B.M.K. Biller, J. Llevadot, N. Rifai, G. Hanson, D. Hayden, A. Klibanski.
Provision of study materials or patients: G. Sesmilo, B.M.K. Biller, A. Klibanski.
Statistical expertise: D. Hayden.
Obtaining of funding: B.M.K. Biller.
Administrative, technical, or logistic support: B.M.K. Biller, G. Hanson.
Collection and assembly of data: G. Sesmilo, B.M.K. Biller, G. Hanson, D. Hayden, A. Klibanski. ARTICLE
Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency
A Randomized, Controlled Clinical Trial
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  P. Abrams, H. Boquete, H. Fideleff, U. Feldt-Rasmussen, P. J Jonsson, M. Koltowska-Haggstrom, P. Wilton, and R. Abs GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables Eur. J. Endocrinol., December 1, 2008; 159(6): 825 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Mallewa, E. Wilkins, J. Vilar, M. Mallewa, D. Doran, D. Back, and M. Pirmohamed HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options J. Antimicrob. Chemother., October 1, 2008; 62(4): 648 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rabkin, I. Awwad, Y. Chen, E. A. Ashley, D. Sun, S. Sood, W. Clusin, P. Heidenreich, G. Piecha, and M.-L. Gross Low-Dose Growth Hormone is Cardioprotective in Uremia J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1774 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lo, S. M. You, B. Canavan, J. Liebau, G. Beltrani, P. Koutkia, L. Hemphill, H. Lee, and S. Grinspoon Low-Dose Physiological Growth Hormone in Patients With HIV and Abdominal Fat Accumulation: A Randomized Controlled Trial JAMA, August 6, 2008; 300(5): 509 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Utz, A. Yamamoto, L. Hemphill, and K. K. Miller Growth Hormone Deficiency by Growth Hormone Releasing Hormone-Arginine Testing Criteria Predicts Increased Cardiovascular Risk Markers in Normal Young Overweight and Obese Women J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2507 - 2514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Beauregard, A. L. Utz, A. E. Schaub, L. Nachtigall, B. M. K. Biller, K. K. Miller, and A. Klibanski Growth Hormone Decreases Visceral Fat and Improves Cardiovascular Risk Markers in Women with Hypopituitarism: A Randomized, Placebo-Controlled Study J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2063 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Joaquin, E Aguilera, M L Granada, M C Pastor, I Salinas, N Alonso, and A Sanmarti Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur. J. Endocrinol., April 1, 2008; 158(4): 483 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. M. Oliveira, M. H. Aguiar-Oliveira, A. D'Oliveira Jr, R. M. C. Pereira, C. R. P. Oliveira, C. T. Farias, J. A. Barreto-Filho, F. D. Anjos-Andrade, C. Marques-Santos, A. C. Nascimento-Junior, et al. Congenital Growth Hormone (GH) Deficiency and Atherosclerosis: Effects of GH Replacement in GH-Naive Adults J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4664 - 4670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Devin, L. S. Blevins Jr., D. K. Verity, Q. Chen, J. R. Bloodworth Jr., J. Covington, and D. E. Vaughan Markedly Impaired Fibrinolytic Balance Contributes to Cardiovascular Risk in Adults with Growth Hormone Deficiency J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3633 - 3639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Lawson, K. K. Miller, V. A. Mathur, M. Misra, E. Meenaghan, D. B. Herzog, and A. Klibanski Hormonal and Nutritional Effects on Cardiovascular Risk Markers in Young Women J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3089 - 3094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Franco, B. Andersson, L. Lonn, B.-A. Bengtsson, J. Svensson, and G. Johannsson Growth Hormone Reduces Inflammation in Postmenopausal Women with Abdominal Obesity: A 12-Month, Randomized, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2644 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Schrager, E. J. Metter, E. Simonsick, A. Ble, S. Bandinelli, F. Lauretani, and L. Ferrucci Sarcopenic obesity and inflammation in the InCHIANTI study J Appl Physiol, March 1, 2007; 102(3): 919 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Abs, U. Feldt-Rasmussen, A. F Mattsson, J. P Monson, B.-A. Bengtsson, M. I Goth, P. Wilton, and M. Koltowska-Haggstrom Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur. J. Endocrinol., July 1, 2006; 155(1): 79 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Holmes, M. J. Watt, and M. A. Febbraio Suppressing lipolysis increases interleukin-6 at rest and during prolonged moderate-intensity exercise in humans J Appl Physiol, August 1, 2004; 97(2): 689 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Cappola, Q.-L. Xue, L. Ferrucci, J. M. Guralnik, S. Volpato, and L. P. Fried Insulin-Like Growth Factor I and Interleukin-6 Contribute Synergistically to Disability and Mortality in Older Women J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2019 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Vongpatanasin, M. Tuncel, Z. Wang, D. Arbique, B. Mehrad, and I. Jialal Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1358 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Murray and S. M. Shalet Adult Growth Hormone Replacement: Lessons Learned and Future Direction J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4427 - 4428. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Buijs, J. Burggraaf, J. G. Langendonk, R. C. Schoemaker, M. Frolich, J.-W. Arndt, A. F. Cohen, J. A. Romijn, M. T. Ackermans, H. P. Sauerwein, et al. Hyposomatotropism Blunts Lipolysis in Abdominally Obese Women J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3851 - 3858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sesmilo, K. K. Miller, and A. Klibanski Cardiovascular Risk in Women with Hypopituritarism J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3509 - 3510. [Full Text] [PDF]
|
|
|
|
|
|
G. Sesmilo, W. P. Fairfield, L. Katznelson, K. Pulaski, P. U. Freda, V. Bonert, E. Dimaraki, S. Stavrou, M. L. Vance, D. Hayden, et al. Cardiovascular Risk Factors in Acromegaly before and after Normalization of Serum IGF-I Levels with the GH Antagonist Pegvisomant J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1692 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sesmilo, K. K. Miller, D. Hayden, and A. Klibanski Inflammatory Cardiovascular Risk Markers in Women with Hypopituitarism J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5774 - 5781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Muller, F. W. G. Leebeek, J. A. M. J. L. Janssen, S. W. J. Lamberts, L. Hofland, and A. J. van der Lely Acute Effect of Pegvisomant on Cardiovascular Risk Markers in Healthy Men: Implications for the Pathogenesis of Atherosclerosis in GH Deficiency J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5165 - 5171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Thomas and L. Berglund Growth Hormone and Cardiovascular Disease: An Area in Rapid Growth J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1871 - 1873. [Full Text]
|
|
|
|
 |
|
 P. M. Ridker High-Sensitivity C-Reactive Protein : Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease Circulation, April 3, 2001; 103(13): 1813 - 1818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sesmilo, B. M. K. Biller, J. Llevadot, D. Hayden, G. Hanson, N. Rifai, and A. Klibanski Effects of Growth Hormone (GH) Administration on Homocyst(e)ine Levels in Men with GH Deficiency: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1518 - 1524. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. J. Cohen Editorial: In Search of the Underlying Mechanisms of Frailty J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2000; 55(12): 706M - 708. [Full Text]
|
|
|
|
 |
|
 Growth Hormone and Cardiovascular Risk Markers Journal Watch Cardiology, September 29, 2000; 2000(929): 9 - 9. [Full Text]
|
|
Article
